Tests

Test Name STAT Turnaround Time Draw Kit Available (Y/N) Sample Requirement
ADAMTS-13 Activity < 24 hours (7 days a week) Yes citrated plasma
Heparin (UFH) Level < 24 hours No citrated plasma
Heparin Antibody Confirmation < 24 hours (M-F) Yes serum
Platelet Aggregation Study – Comprehensive < 24 hours No citrated whole blood
Warfarin Sensitivity Genotype (CYP2C9 and VKORC1) < 24 hours No EDTA whole blood
Von Willebrand Factor Multimer < 5 days No citrated plasma
Von Willebrand Factor Antigen < 24 hours No citrated plasma
Thrombin/Antithrombin Complex < 1 week No citrated plasma
Thrombin Time < 24 hours No citrated plasma
Thrombin Generation (normalized-ETP) < 24 hours No citrated plasma
Russell Viper Venom Time (dilute) < 24 hours No citrated plasma
Rivaroxaban (Xeralto) Level < 24 hours No citrated plasma
Ristocetin-induced Platelet Aggregation < 24 hours No citrated whole blood
Ristocetin Cofactor Activity < 24 hours No citrated plasma
Reptilase Clotting Time < 1 week No citrated plasma
PT Mixing Study < 24 hours No citrated plasma
Prothrombin Time < 24 hours No citrated plasma
Prothrombin Gene Mutation < 24 hours No EDTA whole blood
Prothrombin Fragment 1.2 (F1.2) < 1 week No citrated plasma
Protein S Antigen (Total) < 1 week No citrated plasma
Protein S Antigen (Free) < 1 week No citrated plasma
Protein S Activity < 24 hours No citrated plasma
Protein C Antigen < 1 week No citrated plasma
Protein C Activity < 24 hours No citrated plasma
Plavix Sensitivity – LTA (ADP-induced Platelet Inhibition) < 24 hours No citrated whole blood
Brilinta Sensitivity – LTA (ADP-induced Platelet Inhibition) < 24 hours No citrated whole blood
Ticagrelor Sensitivity – LTA (ADP-induced Platelet Inhibition) < 24 hours citrated whole blood
Aspirin Sensitivity – LTA (AA-induced Platelet Inhibition) < 24 hours No citrated whole blood
Plavix Sensitivity – Genotype (CYP2C19 Genotyping) < 24 hours No EDTA whole blood
Platelet Antibody ID – Indirect (GPIIb/IIIa, GP Ib/IX, GPIa/IIa) < 24 hours No serum
Platelet Antibody ID – Direct (GPIIb/IIIa, GP Ib/IX, GPIa/IIa) < 24 hours No EDTA whole blood
Platelet Electron Microscopy Study < 5 days No ACD whole blood
Plasminogen Antigen < 5 days No citrated plasma
Plasminogen Activity < 5 days No citrated plasma
Plasminogen Activator Inhibitor Activity < 10 days No citrated plasma
MTHFR (C677T) Gene Mutation < 24 hours No EDTA whole blood
MTHFR (A1298C) Gene Mutation < 1 week No EDTA whole blood
Lupus Anticoagulant Index < 24 hours No citrated plasma
Inhibitor Titer (PT Factors) < 24 hours No citrated plasma
Inhibitor Titer (aPTT Factors) < 24 hours No citrated plasma
Inhibitor Screen (PT Factors) < 24 hours No citrated plasma
Inhibitor Screen (aPTT Factors) < 24 hours No citrated plasma
Homocysteine < 5 days No serum
Hexagonal Phospholipid aPTT < 1 week No citrated plasma
Heparin (LMWH) Level < 24 hours No citrated plasma
Heparin Antibody ELISA (reflex) < 24 hours (7 days a week) Yes serum
Fondaparinux (Arixtra) Level < 24 hours No citrated plasma
Fibrinogen Antigen < 1 week No citrated plasma
Fibrinogen Activity < 24 hours No citrated plasma
Factor XIII (13) Activity – Quantitative < 1 week No citrated plasma
Factor XII (12) Activity < 24 hours No citrated plasma
Factor XI (11) Activity < 24 hours No citrated plasma
Factor X (10) Antigen < 1 week No citrated plasma
Factor X (10) Activity – Chromogenic < 1 week No citrated plasma
Factor X (10) Activity < 24 hours No citrated plasma
Factor IX (9) Activity < 24 hours No citrated plasma
Factor VIII (8) Activity < 24 hours No citrated plasma
Factor VII (7) Activity < 24 hours No citrated plasma
Factor V (5) Leiden Gene Mutation < 24 hours No EDTA whole blood
Factor V (5) Activity < 24 hours No citrated plasma
Factor II (2) Activity < 24 hours No citrated plasma
Euglobulin Clot Lysis Time < 1 week No citrated plasma
Dabigatran (Pradaxa) Level < 24 hours No citrated plasma
Beta-2 Glycoprotein I Antibody (IgG, IgM, IgA) < 1 week No serum
aPTT-FS Mixing Study < 24 hours No citrated plasma
aPTT-LA Mixing Study < 24 hours No citrated plasma
aPTT-LA (Lupus Sensitive Reagent) < 24 hours No citrated plasma
aPTT-FS (Factor Sensitive Reagent) < 24 hours No citrated plasma
aPTT Mixing Study < 24 hours No citrated plasma
aPTT < 24 hours No frozen
Antithrombin III Antigen < 1 week No citrated plasma
Antithrombin III Activity < 24 hours No citrated plasma
Anticardiolipin Antibody (IgG, IgM, IgA) < 5 days No serum
Alpha-2 Antiplasmin Activity < 1 week No citrated plasma
ADAMTS-13 Inhibitor < 24 hours (7 days a week) Yes citrated plasma
ADAMTS-13 Antibody < 1 week Yes citrated plasma
Activated Protein C – Resistance < 1 week No citrated plasma
Panels
Order Forms
Collection Guide
Education and Publications
Clinical Trial Services
Patients

Panels

Panel Name STAT Turnaround Time Draw Kit Available (Y/N) Sample Requirement
Hypercoagulability Panel < 24 hours No citrated plasma
Prolonged PT Evaluation Panel < 24 hours No citrated plasma
Prolonged aPTT Evaluation Panel < 24 hours No citrated plasma
Plavix Sensitivity Panel < 24 hours Yes citrated whole blood
Mild Bleeding Disorder Panel < 24 hours No citrated whole blood
Lupus Anticoagulant Screen < 24 hours No citrated plasma
von Willebrand Factor Profile with Multimer < 5 days No citrated plasma
Platelet Aggregation Study – Comprehensive < 24 hours No citrated whole blood
Heparin Antibody Confirmation Panel < 24 hours (M-F) Yes serum
Dysfibrinogenemia Panel < 24 hours No citrated plasma
Antiphospholipid Antibody Panel < 1 week Yes serum
aHUS Genetic Panel < 48 hours (M-F) Yes EDTA whole blood

Tests

Test Name STAT Turnaround Time Draw Kit Available (Y/N) Sample Requirement
ADAMTS-13 Activity < 24 hours (7 days a week) Yes citrated plasma
Heparin (UFH) Level < 24 hours No citrated plasma
Heparin Antibody Confirmation < 24 hours (M-F) Yes serum
Platelet Aggregation Study – Comprehensive < 24 hours No citrated whole blood
Warfarin Sensitivity Genotype (CYP2C9 and VKORC1) < 24 hours No EDTA whole blood
Von Willebrand Factor Multimer < 5 days No citrated plasma
Von Willebrand Factor Antigen < 24 hours No citrated plasma
Thrombin/Antithrombin Complex < 1 week No citrated plasma
Thrombin Time < 24 hours No citrated plasma
Thrombin Generation (normalized-ETP) < 24 hours No citrated plasma
Russell Viper Venom Time (dilute) < 24 hours No citrated plasma
Rivaroxaban (Xeralto) Level < 24 hours No citrated plasma
Ristocetin-induced Platelet Aggregation < 24 hours No citrated whole blood
Ristocetin Cofactor Activity < 24 hours No citrated plasma
Reptilase Clotting Time < 1 week No citrated plasma
PT Mixing Study < 24 hours No citrated plasma
Prothrombin Time < 24 hours No citrated plasma
Prothrombin Gene Mutation < 24 hours No EDTA whole blood
Prothrombin Fragment 1.2 (F1.2) < 1 week No citrated plasma
Protein S Antigen (Total) < 1 week No citrated plasma
Protein S Antigen (Free) < 1 week No citrated plasma
Protein S Activity < 24 hours No citrated plasma
Protein C Antigen < 1 week No citrated plasma
Protein C Activity < 24 hours No citrated plasma
Plavix Sensitivity – LTA (ADP-induced Platelet Inhibition) < 24 hours No citrated whole blood
Brilinta Sensitivity – LTA (ADP-induced Platelet Inhibition) < 24 hours No citrated whole blood
Ticagrelor Sensitivity – LTA (ADP-induced Platelet Inhibition) < 24 hours citrated whole blood
Aspirin Sensitivity – LTA (AA-induced Platelet Inhibition) < 24 hours No citrated whole blood
Plavix Sensitivity – Genotype (CYP2C19 Genotyping) < 24 hours No EDTA whole blood
Platelet Antibody ID – Indirect (GPIIb/IIIa, GP Ib/IX, GPIa/IIa) < 24 hours No serum
Platelet Antibody ID – Direct (GPIIb/IIIa, GP Ib/IX, GPIa/IIa) < 24 hours No EDTA whole blood
Platelet Electron Microscopy Study < 5 days No ACD whole blood
Plasminogen Antigen < 5 days No citrated plasma
Plasminogen Activity < 5 days No citrated plasma
Plasminogen Activator Inhibitor Activity < 10 days No citrated plasma
MTHFR (C677T) Gene Mutation < 24 hours No EDTA whole blood
MTHFR (A1298C) Gene Mutation < 1 week No EDTA whole blood
Lupus Anticoagulant Index < 24 hours No citrated plasma
Inhibitor Titer (PT Factors) < 24 hours No citrated plasma
Inhibitor Titer (aPTT Factors) < 24 hours No citrated plasma
Inhibitor Screen (PT Factors) < 24 hours No citrated plasma
Inhibitor Screen (aPTT Factors) < 24 hours No citrated plasma
Homocysteine < 5 days No serum
Hexagonal Phospholipid aPTT < 1 week No citrated plasma
Heparin (LMWH) Level < 24 hours No citrated plasma
Heparin Antibody ELISA (reflex) < 24 hours (7 days a week) Yes serum
Fondaparinux (Arixtra) Level < 24 hours No citrated plasma
Fibrinogen Antigen < 1 week No citrated plasma
Fibrinogen Activity < 24 hours No citrated plasma
Factor XIII (13) Activity – Quantitative < 1 week No citrated plasma
Factor XII (12) Activity < 24 hours No citrated plasma
Factor XI (11) Activity < 24 hours No citrated plasma
Factor X (10) Antigen < 1 week No citrated plasma
Factor X (10) Activity – Chromogenic < 1 week No citrated plasma
Factor X (10) Activity < 24 hours No citrated plasma
Factor IX (9) Activity < 24 hours No citrated plasma
Factor VIII (8) Activity < 24 hours No citrated plasma
Factor VII (7) Activity < 24 hours No citrated plasma
Factor V (5) Leiden Gene Mutation < 24 hours No EDTA whole blood
Factor V (5) Activity < 24 hours No citrated plasma
Factor II (2) Activity < 24 hours No citrated plasma
Euglobulin Clot Lysis Time < 1 week No citrated plasma
Dabigatran (Pradaxa) Level < 24 hours No citrated plasma
Beta-2 Glycoprotein I Antibody (IgG, IgM, IgA) < 1 week No serum
aPTT-FS Mixing Study < 24 hours No citrated plasma
aPTT-LA Mixing Study < 24 hours No citrated plasma
aPTT-LA (Lupus Sensitive Reagent) < 24 hours No citrated plasma
aPTT-FS (Factor Sensitive Reagent) < 24 hours No citrated plasma
aPTT Mixing Study < 24 hours No citrated plasma
aPTT < 24 hours No frozen
Antithrombin III Antigen < 1 week No citrated plasma
Antithrombin III Activity < 24 hours No citrated plasma
Anticardiolipin Antibody (IgG, IgM, IgA) < 5 days No serum
Alpha-2 Antiplasmin Activity < 1 week No citrated plasma
ADAMTS-13 Inhibitor < 24 hours (7 days a week) Yes citrated plasma
ADAMTS-13 Antibody < 1 week Yes citrated plasma
Activated Protein C – Resistance < 1 week No citrated plasma

Order Forms

Machaon Diagnostics has provided several downloadable documents to assist in ordering, processing and billing. Below please find links to our most frequently requested documents.

Collection Guide

Specimen processing is one of the most important aspects in the generation of accurate and reliable lab results. Many variables, such as, anticoagulant ratio, storage time and temperature, and surface of containers and drawing components can effect test results.

Machaon Diagnostics follows and recommends the use of the third edition of the National Committee for Clinical Laboratory Standards (NCCLS) guideline H21-A3: Collection, Transport, and Processing of Blood Specimens for Coagulation Testing and General Performance of Coagulation Assays.

Please contact the lab with any shipping questions

Specimen Collection

Frozen Citrated Plasma
Frozen citrated plasma is the specimen of choice for clotting assays and some ELISA testing. The anticoagulant used for these assays is 105 – 109 mmol/L, 3.13% – 3.2% of the dihydrate form of trisodium citrate (Na3C6H5O7 2H2O), buffered or nonbuffered.

Patients with hematocrit values above 55% should have their final citrate concentration corrected using the following equation:

X = (100 – PCV) / (595 – PCV) WB Volume

Where X is citrate volume required to prepare a whole blood volume (WB Volume) from a patient with a certain percent packed cell volume (PCV).

Please follow the listed suggestions for collection of citrated plasma samples.

  • A 1:9 ratio of anticoagulant to whole blood is imperative
  • Blood should be drawn directly into anticoagulant if possible
  • Syringe draws should be added to anticoagulant within 1 minute
  • Syringe draws should use no more that a 20mL volume syringe
  • A two-syringe technique is preferred for syringe draws
  • Coagulation draws should be the 2nd or 3rd tube drawn
  • Catheter draws should be avoided or under the advise of the attending physician
  • All tubes should be inverted at least 4 times to ensure adequate mixing
  • Suitable needle gauges range from 19 – 22 for coagulation and platelet testing
  • Cell-free plasma must contain less than 10,000 platelets/µL
  • Centrifugation should be performed at 1,500 × g for 15 or more minutes
  • Aliquots are frozen (<= -20ºC) promptly to minimize factor degradation
  • Specimens are shipped frozen on dry ice (-78.5ºC)

Frozen Serum
Frozen serum is the specimen of choice for most immunoglobulin detecting assays and many ELISA based tests. Whole blood is drawn into a glass or plastic tube possibly containing an activator. Please follow the tube manufacturer’s guidelines for tube handling and processing.

Please follow the listed suggestions for collection of serum samples.

  • Plastic tubes containing an activator should be inverted at least 4 times
  • Glass tubes without activator should be clotted for 2 hours at room temperature
  • Suitable needle gauges range from 19 – 22 for the serum based tests
  • Centrifugation should be performed at 1,500 × g for 15 or more minutes
  • Aliquots are frozen (<= -20ºC) before shipping and shipped on dry ice (-78.5ºC

EDTA Whole Blood
EDTA anticoagulated whole blood is the specimen of choice for molecular genetic tests.

Please follow the listed suggestions for collection of genetic samples.

  • Blood should be drawn directly into anticoagulant if possible
  • This must be a closed system draw to prevent contamination
  • All tubes should be inverted at least 4 times to ensure adequate mixing
  • Suitable needle gauges range from 19 – 22 to prevent cell lysis
  • A minimum of 2mL of whole blood is needed for genetic assays
  • No processing is required for this sample type
  • Ship this type of specimen at room temperature

Aliquoting Specimens
Submitting multiple aliquots (plasma or serum) for testing is an important aspect of clot, chromogenic and ELISA based tests. Aliquots of 1mL are requested for most of our assays. These should be frozen prior to shipment in a <= -20 C freezer or colder. Tubes should be placed into a rack to ensure the samples are frozen properly in the base of the tube. Freezing should occur within 1 hour of the time of draw. Please refer to the preferred number of aliquots when submitting samples.

Shipping

Shipment is a crucial aspect of clinical testing. Please follow the below instructions for easy shipments to the lab.

Local Shippers
Machaon Diagnostics contracts with Medical Couriers, Inc. (MCI). who service the entire San Francisco Bay Area and surrounding areas. MCI has a fleet of specially trained drives that will visit your lab, clinic or office during specified times. Couriers carry dry ice, cold packs and room temperature containers for receipt of all specimen types.

Medical Couriers, Inc. can be phoned for individual pickup requests at the below number.

Medical Couriers, Inc.
(800)-652-1147

Place prepare samples and order form in a shipping bag with Machaon and specimen type written in a clear and visible location.

Out-of-area Shippers
Please collect the following items:

  • Test Order Form
  • Packing material or newspaper
  • Styrofoam container, possibly with outer cardboard box
  • Packaging tape
  • Airbill for overnight shipments
  • ORM-A label for dry ice shipments (UN1845)
  • Dry ice (-78.5ºC) sufficient for transit time (5lb. per day)
  • Specimens in biohazard specimen transport bag

Packaging
Place the biohazard bag containing samples and the test order form into a Styrofoam container followed by dry ice. Fill remaining container space with packaging material and seal with packaging tape. Adhere a completed airbill and dry ice labels to the exterior of container in a visible location. Telephone your preferred overnight courier to request a pickup or place container in designated pickup area.

Please contact the lab with any shipping questions

Education and Publications

Education

Diagnosing Thrombotic Microangiopathies: TTP and atypical HUS: (A Grand Rounds presentation at Mattel Children’s Hospital, UCLA, to Pediatric Nephrology with Dr. Brad Lewis.)

 

Publications

Stromsness B. et al. Perceived clinical utility of ADAMTS-13 testing decreases quickly when turnaround time extends beyond two days. Int J Lab Hematol. 2015; (abstract).

Ero M. et al. Novel variant detection is essential when attempting to genetically confirm the clinical diagnosis of complement-mediated thrombotic microangiopathies (TMA). J Clin Apheresis. 2015; (abstract O-09).

Harbert J. et al. Inhibitory effects of fish oil on platelet-associated thrombin generation as measured by the calibrated automated thrombogram: an in vitro study. Int Soc Thromb Hemost 2014; (abstract 604).

Ero M. et al. Impact of telavancin on prothrombin time and activated partial thromboplastin time as determined using point-of-care coagulometers. J Thromb Thrombolysis. 2013;38(2):235-240.

Beattie DT. Et al. An in vitro investigation of the cardiovascular effects of the 5-HT4 receptor selective agonists, Velusetrag and TD-8954. J Thromb Thrombolysis. Vascular Pharmacology. 2013;58:150–156.

Ero M. et al. A pilot study on the serum pharmacokinetics of nattokinase in humans following a single oral daily dose. Alternative Therapies. 2013;19(3): 18-21.

Higgins D. et al. The inability of tegaserod to affect platelet aggregation and coronary artery tone at supratherapeutic concentrations. Archives of Pharmacology. 2012;385(1):103-9.

Ng C. et al. Oral bioavailability of nattokinase (NSK-SD). Am J Clin Pathol. 2010;134(suppl):11.

Lakshmi P. et al. Flavocoxid, an anti-inflammatory agent of botanical origin, does not affect coagulation or interact with anticoagulation therapies. Adv Ther. 2010;27(7):1-12.

Jeske WP. et al. Isolation and characterization of heparin from tuna skins. Clin Appl Thromb Hemost. 2007 Apr;12(2):137-45.

Fareed D. et al. Nitric oxide levels are upregulated in patients with malignancy-associated hypercoagulable state. Int J Lab Hematol. 2005; (abstract).

Jeske WP. et al. A survey of venous thrombosis models. Methods Mol Med. 2004;93:221-37.

Sahud et al. von Willebrand factor-cleaving protease inhibitor in a patient with human immunodeficiency syndrome-associated thrombotic thrombocytopenic purpura. Br J Haematol. 2002; 116(4):909-911.

Fenton JW. et al. Statin drugs and dietary isoprenoids downregulate protein prenylation in signal transduction and are antithrombotic and prothrombolytic agents. Biochemistry. 2002;67(1):85-91.

Ero M. et al. Comparative effects of a novel sulfated pentamannan oligosaccaride mixture (PI-88), heparin and related agents on the tissue factor-induced platelet activation and aggregation profile in whole blood. Thromb Haemost. 2001; (abstract 6260).

Ero M. et al. An antiplatelet drug, ticlopidine, inhibits heparin-induced thrombocytopenia responses as measured by platelet aggregometry and 14C serotonin release. Thromb Haemostasis. 1997; (abstract).

Clinical Trial Services

Machaon Diagnostics provides a rapid and complete solution for companies in need of clinical trial services, contract research and independent marketing claim validation. Our team of scientists has over 100 years of clinical study expertise. Machaon Diagnostics has been performing studies on pharmaceuticals, dietary supplements, functional foods and other agents since 2003. Design, subject recruitment, sample collection/storage, testing, statistical analysis, study reporting and manuscript preparation are all included in our comprehensive service. We have an extensive database of well-characterized study volunteers, allowing us to provide some IRB-approved clinical trials in as little as 1 month. Our subject database includes normal adult, elevated risk of cardiovascular disease, high blood pressure, metabolic syndrome and other populations.

Machaon Diagnostics is a California-licensed, CLIA-accredited, College of American Pathologists (CAP)-accredited clinical laboratory authorized to provide high complexity clinical laboratory services. All laboratory testing is controlled within our Quality Assurance Program and studies are offered in a Good Laboratory Practices (GLP, 21CFR Part 58)/ EN 13612 environment.

Research & Development

Machaon Diagnostics is California’s only independent specialized coagulation lab. We are a privately owned company, staffed by CA-licensed clinical laboratory scientists under the direction of a hematologist medical director.

As a clinical lab, we provide a unique testing environment for evaluating thrombotic, fibrinolytic potential. Pharmaceutical, device and biotech compounds and materials can be studied within established, validated and controlled clinical assays with verified reference ranges. Our clinical tests are further controlled within our quality assurance and proficiency testing policies and procedures. All tests can be modified or re-designed for best-fit analysis.

Machaon Diagnostics is a California-licensed, CLIA-accredited, College of American Pathologists (CAP)-accredited clinical laboratory authorized to provide high complexity clinical laboratory services. All laboratory testing is controlled within our Quality Assurance Program and studies are offered in a Good Laboratory Practices (GLP, 21CFR Part 58)/ EN 13612 environment.

The Machaon Diagnostics laboratory facility is located on a medical center campus in Oakland, California and is staffed with over 100 years of in-house esoteric coagulation and platelet testing experience. All lab scientists are published in and passionate about the field thrombosis and hemostasis. Please contact us if we may help with your next study.

Please contact the laboratory to inquire about this service.

Assay Development

Medical procedures, devices, novel agents and methodologies must be evaluated for their impact on coagulation and platelet systems if there is suspected bleeding or clotting potential.

Our staff has had extensive experience designing unique testing systems or applying the proper testing system to answer the client’s questions quickly and accurately.

Machaon Diagnostics is a California-licensed, CLIA-accredited, College of American Pathologists (CAP)-accredited clinical laboratory authorized to provide high complexity clinical laboratory services. All laboratory testing is controlled within our Quality Assurance Program and studies are offered in a Good Laboratory Practices (GLP, 21CFR Part 58)/ EN 13612 environment.

Please contact the laboratory to inquire about this service.

Patients

What you need to know

If you are reading this page, it likely means your doctor has ordered a bleeding or clotting test for you and would like you to get this test run at Machaon Diagnostics. Machaon Diagnostics is a clinical reference lab specializing in bleeding and clotting testing, one of the few independent coagulation labs in the country. We run very specific, unique blood tests which are often critical in helping doctors determine the correct course of treatment.

Machaon Diagnostics provides specialized lab testing to hospitals and doctors all over the country and is recognized for the speed and quality of our testing.

It is important to know that your insurance may or may not cover your testing. We have a long track record of working with patients to ensure they get the testing they need and we will work with you to help find a solution should your insurance not cover the testing we would provide.

If you are coming in to Machaon for a test, here are some things you will need to have with you:

  • Your doctors lab order
  • Your insurance information
  • Your identification
  • A list of your current medications
  • If you are coming in for a Platelet Aggregation, please remember you must fast before this test.

Machaon Diagnostics was founded in 2003 and is a California-licensed, CLIA-accredited, College of American Pathologists (CAP)-accredited clinical laboratory authorized to provide high complexity clinical laboratory services. All laboratory testing is controlled within our Quality Assurance Program and studies are offered in a Good Laboratory Practices (GLP, 21CFR Part 58)/ EN 13612 environment.

Please contact the laboratory if you have questions.